Exelixis, Inc. (EXEL) Shares Bought by Mackenzie Financial Corp
Mackenzie Financial Corp increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 24.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,116 shares of the biotechnology company’s stock after purchasing an additional 1,963 shares during the period. Mackenzie Financial Corp’s holdings in Exelixis were worth $245,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. First Quadrant L P CA increased its stake in Exelixis by 6,771.4% in the 3rd quarter. First Quadrant L P CA now owns 402,528 shares of the biotechnology company’s stock worth $9,753,000 after acquiring an additional 396,670 shares during the last quarter. Prudential Financial Inc. increased its stake in Exelixis by 262.0% in the 2nd quarter. Prudential Financial Inc. now owns 627,530 shares of the biotechnology company’s stock worth $15,456,000 after acquiring an additional 454,197 shares during the last quarter. GAM Holding AG bought a new stake in Exelixis in the 2nd quarter worth approximately $1,256,000. Macquarie Group Ltd. bought a new stake in Exelixis in the 2nd quarter worth approximately $3,449,000. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in Exelixis by 583.1% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 659,592 shares of the biotechnology company’s stock worth $16,246,000 after acquiring an additional 563,040 shares during the last quarter. 81.19% of the stock is currently owned by institutional investors.
A number of research firms have issued reports on EXEL. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective (up previously from $28.00) on shares of Exelixis in a research note on Tuesday, September 12th. Cann reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Royal Bank of Canada began coverage on Exelixis in a research note on Thursday, September 14th. They issued an “outperform” rating and a $32.00 price objective on the stock. Leerink Swann downgraded Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. Finally, Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research note on Wednesday, October 18th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $31.38.
Exelixis, Inc. (NASDAQ EXEL) opened at $26.84 on Wednesday. The firm has a market capitalization of $7,816.44, a P/E ratio of 51.80, a PEG ratio of 1.18 and a beta of 1.89. Exelixis, Inc. has a 12-month low of $14.22 and a 12-month high of $32.50.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.18. The firm had revenue of $152.50 million for the quarter, compared to the consensus estimate of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company’s revenue for the quarter was up 145.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS. equities analysts anticipate that Exelixis, Inc. will post 0.49 earnings per share for the current year.
In other news, Director Stelios Papadopoulos sold 72,210 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $27.76, for a total transaction of $2,004,549.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $24.28, for a total value of $662,892.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 770,152 shares of company stock worth $20,556,457. Corporate insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.